Docetaxel Combined With Carboplatin Plus Anlotinib as First Line Treatment in NSCLC
Status:
Unknown status
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
Anlotinib which has shown an affirmatory efficacy in ALTER0303 controlled trial as a 3rd-line
treatment on advanced NSCLC is a tyrosine kinase inhibitor with a favorable safety profile in
phase I trial which mainly targets VEGFR1/2/3, FGFR, PDGFR and c-kit. The purpose of this
trail is to establish whether advanced non-squamous NSCLC patients could benefit from the
combination treatment of docetaxel, carboplatin and anlotinib as the first-line and
maintenance treatment.